NCT05319769

Brief Summary

In electrophysiology, interventional procedures are often assisted by fluoroscopic guidance, exposing both patients and healthcare professionals to a considerable dose of radiation. Catheter ablation of atrial fibrillation has frequently involved the use of fluoroscopy: in fact, it incorporates greater complexity due to the need to perform the transseptal puncture. A visible introducer in the 3D electro-anatomical mapping system (which does not involve the use of X-rays), has become an important tool for performing transseptal puncture: in particular, it is positioned at level of the oval fossa of the right atrium (puncture site); subsequently, the needle is introduced inside it; the intervention is guided both by electroanatomical mapping and by the use of intracardiac echocardiography for the identification of important anatomical landmarks. The "zero rays" technique represents a valid alternative to fluoroscopic guidance, widely used and validated over the years. In fact, X-ray exposure in an atrial fibrillation ablation procedure can reach up to 60 mSv: the radiological risk makes it necessary to study safe and effective alternative techniques. In this retrospective, observational and monocentric study, 50 catheter ablation procedures of atrial fibrillation will be examined, divided into two groups:

  1. 1.25 patients who performed this procedure according to the classic approach, ie under fluoroscopic guidance;
  2. 2.25 patients who performed this procedure using an ablative approach that involved the use of the introducer in combination with the 3D EAM system and intracardiac echocardiography.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2020

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2021

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

March 31, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 8, 2022

Completed
Last Updated

April 8, 2022

Status Verified

March 1, 2022

Enrollment Period

1.1 years

First QC Date

March 31, 2022

Last Update Submit

March 31, 2022

Conditions

Keywords

atrial fibrillationablationradiofrequencyintracardiac echocardiographyzero fluoroscopyarrhythmias

Outcome Measures

Primary Outcomes (3)

  • Fluoroscopy time

    Time of X-ray exposure

    Intraprocedure

  • DAP

    Dose area product

    Intraprocedure

  • Procedural time

    Total procedure time

    Intraprocedure

Secondary Outcomes (3)

  • Time for PVI

    Intraprocedure

  • Complications

    30 days

  • Absence of atrial fibrillation recurrence

    6 months

Study Arms (2)

Zero fluoroscopy

Zero fluoroscopy Patients undergoing AF ablation using the steerable introducer in combination with the 3D EAM system and intracardiac echocardiography. Reconstruction of a bipolar map of the right atrium with a mapping catheter. Then, the interatrial septum is reconstructed and the oval fossa is defined. Transseptal puncture is performed using the steerable introducer (which can be viewed on the EAM) through which, a transseptal needle is introduced. The introducer is positioned at the fossa ovalis. The transseptal needle is advanced to perform the puncture of the septum. After accessing the left atrium, the mapping catheter is introduced iusing the introducer, with which all the structures of the left atrium are mapped. In addition, with intracardiac echocardiography, it is possible to identify important structures such as the pulmonary veins and the esophagus. The pulmonary veins are isolated by means of a catheter.

Procedure: Atrial fibrillation ablation

Traditional approach

Traditional approach Patients who have undergone atrial fibrillation ablation procedure using the traditional approach. The procedure is based on 3D reconstruction using intracardiac ultrasound first and then electroanatomical mapping of the left atrium through a transseptal approach guided by integration of fluoroscopy and intracardiac ultrasound. The transseptal puncture is performed using a transseptal needle which is brought into place using a long introducer with a dilator. The fluoroscopic support is essential as the introducer is not viewable with 3D mapping systems. After accessing the left atrium, through the previously used introducer, a mapping catheter is taken to the left atrium for electro-anatomical reconstruction. Subsequently, the antral pulmonary veins are isolated by means of an ablator catheter with irrigated tip.

Procedure: Atrial fibrillation ablation

Interventions

Pulmonary vein isolation

Traditional approachZero fluoroscopy

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with atrial fibrillation (paroxysmal or persistent) treated with transcatheter ablation

You may qualify if:

  • Paroxysmal or persistent atrial fibrillation
  • Atrial fibrillation ablation performed during study period
  • Clinical follow-up and ECG-Holter recording during follow-up

You may not qualify if:

  • Age \< 18 years
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Matteo Bertini

Ferrara, 44124, Italy

Location

MeSH Terms

Conditions

Atrial FibrillationArrhythmias, Cardiac

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 31, 2022

First Posted

April 8, 2022

Study Start

June 1, 2020

Primary Completion

June 30, 2021

Study Completion

December 31, 2021

Last Updated

April 8, 2022

Record last verified: 2022-03

Locations